Cannabidiol Possibly Improves Survival of Patients with Pancreatic Cancer: A Case Series

Gerhard Nahler,Rudolf Likar,Gerhard Nahler
DOI: https://doi.org/10.31487/j.cor.2020.08.18
2020-08-18
Clinical Oncology and Research
Abstract:Background: Pancreatic cancer ranks among the deadliest solid tumors. When patients complain about symptoms, the tumor has already spread in the majority of cases to neighbouring tissues and organs with limited possibilities for surgical interventions. In a very recent population-based study which included a total of 36,453 patients with pancreatic ductal adenocarcinoma, median overall survival was only 3.8 months. A growing number of articles suggest potential anticancer benefits of cannabinoids, in particular of cannabidiol (CBD). This is the first time that treatment experiences with CBD are described in patients with pancreatic cancer. Case Series: A total of nine consecutive patients with pancreatic cancer received CBD. All but two received standard chemotherapy in addition, two patients only CBD. CBD was usually administered in an oral daily dose of 400mg. The mean overall survival of these nine patients was 11.5 months (median 11 months). Conclusion: Overall survival seems to be about two times longer than reported in the population-based study mentioned above.
What problem does this paper attempt to address?